Muller & Phipps (Ceylon) Past Earnings Performance
Past criteria checks 2/6
Muller & Phipps (Ceylon) has been growing earnings at an average annual rate of 23.3%, while the Healthcare industry saw earnings growing at 16.8% annually. Revenues have been declining at an average rate of 4.1% per year. Muller & Phipps (Ceylon)'s return on equity is 13%, and it has net margins of 4.7%.
Key information
23.3%
Earnings growth rate
22.5%
EPS growth rate
| Healthcare Industry Growth | 16.6% |
| Revenue growth rate | -4.1% |
| Return on equity | 13.0% |
| Net Margin | 4.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Muller & Phipps (Ceylon) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 728 | 34 | 194 | 0 |
| 30 Jun 24 | 803 | 113 | 151 | 0 |
| 31 Mar 24 | 763 | 75 | 155 | 0 |
| 31 Dec 23 | 702 | 15 | 180 | 0 |
| 30 Sep 23 | 568 | -17 | 167 | 0 |
| 30 Jun 23 | 401 | -52 | 176 | 0 |
| 31 Mar 23 | 527 | -88 | 151 | 0 |
| 31 Dec 22 | 607 | -186 | 108 | 0 |
| 30 Sep 22 | 941 | -119 | 110 | 0 |
| 30 Jun 22 | 1,174 | -117 | 113 | 0 |
| 31 Mar 22 | 1,065 | -37 | 119 | 0 |
| 31 Dec 21 | 1,080 | 129 | 111 | 0 |
| 30 Sep 21 | 907 | 103 | 109 | 0 |
| 30 Jun 21 | 742 | 67 | 113 | 0 |
| 31 Mar 21 | 751 | 67 | 111 | 0 |
| 31 Dec 20 | 779 | -2 | 89 | 0 |
| 30 Sep 20 | 834 | -49 | 117 | 0 |
| 30 Jun 20 | 833 | -74 | 124 | 0 |
| 31 Mar 20 | 847 | -104 | 137 | 0 |
| 31 Dec 19 | 775 | -126 | 166 | 0 |
| 30 Sep 19 | 762 | -119 | 166 | 0 |
| 30 Jun 19 | 928 | -86 | 163 | 0 |
| 31 Mar 19 | 989 | -61 | 147 | 0 |
| 31 Dec 18 | 1,132 | -6 | 156 | 0 |
| 30 Sep 18 | 1,149 | 26 | 151 | 0 |
| 30 Jun 18 | 1,005 | 12 | 148 | 0 |
| 31 Mar 18 | 937 | 3 | 144 | 0 |
| 31 Dec 17 | 823 | -24 | 145 | 0 |
| 30 Sep 17 | 802 | -17 | 141 | 0 |
| 30 Jun 17 | 866 | 12 | 138 | 0 |
| 31 Mar 17 | 899 | 22 | 139 | 0 |
| 31 Dec 16 | 1,009 | 48 | 139 | 0 |
| 30 Sep 16 | 982 | 48 | 139 | 0 |
| 30 Jun 16 | 925 | 31 | 136 | 0 |
| 31 Mar 16 | 903 | 32 | 134 | 0 |
| 31 Dec 15 | 790 | 32 | 129 | 0 |
| 30 Sep 15 | 795 | 38 | 125 | 0 |
| 30 Jun 15 | 776 | 42 | 121 | 0 |
| 31 Mar 15 | 755 | 42 | 116 | 0 |
| 31 Dec 14 | 722 | 37 | 111 | 0 |
| 30 Sep 14 | 622 | 15 | 111 | 0 |
| 30 Jun 14 | 559 | 9 | 107 | 0 |
| 31 Mar 14 | 573 | 12 | 103 | 0 |
| 31 Dec 13 | 531 | 12 | 102 | 0 |
Quality Earnings: MULL.N0000 has a large one-off gain of LKR7.3M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: MULL.N0000 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MULL.N0000 has become profitable over the past 5 years, growing earnings by 23.3% per year.
Accelerating Growth: MULL.N0000 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: MULL.N0000 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (7.5%).
Return on Equity
High ROE: MULL.N0000's Return on Equity (13%) is considered low.